Cargando…
FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition
PURPOSE: To evaluate and model the pharmacokinetic and pharmacodynamic behavior in rats of FG-3019, a human monoclonal antibody targeting connective tissue growth factor (CTGF). METHODS: FG-3019, human CTGF (rhCTGF), or the N-terminal domain of rhCTGF were administered intravenously to rats and conc...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942499/ https://www.ncbi.nlm.nih.gov/pubmed/27059922 http://dx.doi.org/10.1007/s11095-016-1918-0 |
_version_ | 1782442420355465216 |
---|---|
author | Brenner, Mitchell C. Krzyzanski, Wojciech Chou, James Z. Signore, Pierre E. Fung, Cyra K. Guzman, David Li, Dongxia Zhang, Weihua Olsen, David R. Nguyen, Viet-Tam L. Koo, Carolyn W. Sternlicht, Mark D. Lipson, Kenneth E. |
author_facet | Brenner, Mitchell C. Krzyzanski, Wojciech Chou, James Z. Signore, Pierre E. Fung, Cyra K. Guzman, David Li, Dongxia Zhang, Weihua Olsen, David R. Nguyen, Viet-Tam L. Koo, Carolyn W. Sternlicht, Mark D. Lipson, Kenneth E. |
author_sort | Brenner, Mitchell C. |
collection | PubMed |
description | PURPOSE: To evaluate and model the pharmacokinetic and pharmacodynamic behavior in rats of FG-3019, a human monoclonal antibody targeting connective tissue growth factor (CTGF). METHODS: FG-3019, human CTGF (rhCTGF), or the N-terminal domain of rhCTGF were administered intravenously to rats and concentrations of these proteins as well as endogenous CTGF were determined by immunoassays. FG-3019, or (125)I-labeled FG-3019, and human CTGF (rhCTGF) were co-administered to assess the impact of CTGF on the elimination rate and tissue localization of FG-3019, which was further characterized by immunohistochemical analysis. A PK/PD model for target-mediated elimination of FG-3019 was developed to fit the kinetic data. RESULTS: FG-3019 exhibited non-linear pharmacokinetics in rats. Circulating concentrations of the N-terminal half of CTGF increased after dosing with FG-3019, reached maximal levels after 1–5 days, and returned toward baseline levels as FG-3019 cleared from the circulation, whereas the concentration of intact CTGF was unaffected by administration of FG-3019. Co-administration of rhCTGF dramatically enhanced the rate of FG-3019 elimination, redistributing the majority of (125)I-labeled FG-3019 from the blood to the liver, kidney, spleen and adrenal gland. FG-3019 co-administered with CTGF was found along the sinusoids of the liver and adrenal glands, the capillaries of the kidney glomeruli and in the spleen. A pharmacokinetic model for target-mediated elimination of FG-3019 was used to fit the time courses of FG-3019 and endogenous CTGF plasma concentrations, as well as time courses of rhCTGF and rhCTGF N-fragment after intravenous administration of these species. CONCLUSIONS: FG-3019 is subject to target mediated elimination in rats. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11095-016-1918-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4942499 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-49424992016-07-26 FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition Brenner, Mitchell C. Krzyzanski, Wojciech Chou, James Z. Signore, Pierre E. Fung, Cyra K. Guzman, David Li, Dongxia Zhang, Weihua Olsen, David R. Nguyen, Viet-Tam L. Koo, Carolyn W. Sternlicht, Mark D. Lipson, Kenneth E. Pharm Res Research Paper PURPOSE: To evaluate and model the pharmacokinetic and pharmacodynamic behavior in rats of FG-3019, a human monoclonal antibody targeting connective tissue growth factor (CTGF). METHODS: FG-3019, human CTGF (rhCTGF), or the N-terminal domain of rhCTGF were administered intravenously to rats and concentrations of these proteins as well as endogenous CTGF were determined by immunoassays. FG-3019, or (125)I-labeled FG-3019, and human CTGF (rhCTGF) were co-administered to assess the impact of CTGF on the elimination rate and tissue localization of FG-3019, which was further characterized by immunohistochemical analysis. A PK/PD model for target-mediated elimination of FG-3019 was developed to fit the kinetic data. RESULTS: FG-3019 exhibited non-linear pharmacokinetics in rats. Circulating concentrations of the N-terminal half of CTGF increased after dosing with FG-3019, reached maximal levels after 1–5 days, and returned toward baseline levels as FG-3019 cleared from the circulation, whereas the concentration of intact CTGF was unaffected by administration of FG-3019. Co-administration of rhCTGF dramatically enhanced the rate of FG-3019 elimination, redistributing the majority of (125)I-labeled FG-3019 from the blood to the liver, kidney, spleen and adrenal gland. FG-3019 co-administered with CTGF was found along the sinusoids of the liver and adrenal glands, the capillaries of the kidney glomeruli and in the spleen. A pharmacokinetic model for target-mediated elimination of FG-3019 was used to fit the time courses of FG-3019 and endogenous CTGF plasma concentrations, as well as time courses of rhCTGF and rhCTGF N-fragment after intravenous administration of these species. CONCLUSIONS: FG-3019 is subject to target mediated elimination in rats. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1007/s11095-016-1918-0) contains supplementary material, which is available to authorized users. Springer US 2016-04-08 2016 /pmc/articles/PMC4942499/ /pubmed/27059922 http://dx.doi.org/10.1007/s11095-016-1918-0 Text en © The Author(s) 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Research Paper Brenner, Mitchell C. Krzyzanski, Wojciech Chou, James Z. Signore, Pierre E. Fung, Cyra K. Guzman, David Li, Dongxia Zhang, Weihua Olsen, David R. Nguyen, Viet-Tam L. Koo, Carolyn W. Sternlicht, Mark D. Lipson, Kenneth E. FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition |
title | FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition |
title_full | FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition |
title_fullStr | FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition |
title_full_unstemmed | FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition |
title_short | FG-3019, a Human Monoclonal Antibody Recognizing Connective Tissue Growth Factor, is Subject to Target-Mediated Drug Disposition |
title_sort | fg-3019, a human monoclonal antibody recognizing connective tissue growth factor, is subject to target-mediated drug disposition |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4942499/ https://www.ncbi.nlm.nih.gov/pubmed/27059922 http://dx.doi.org/10.1007/s11095-016-1918-0 |
work_keys_str_mv | AT brennermitchellc fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition AT krzyzanskiwojciech fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition AT choujamesz fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition AT signorepierree fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition AT fungcyrak fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition AT guzmandavid fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition AT lidongxia fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition AT zhangweihua fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition AT olsendavidr fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition AT nguyenviettaml fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition AT koocarolynw fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition AT sternlichtmarkd fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition AT lipsonkennethe fg3019ahumanmonoclonalantibodyrecognizingconnectivetissuegrowthfactorissubjecttotargetmediateddrugdisposition |